Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 20.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,964 shares of the company’s stock after acquiring an additional 844 shares during the period. Sanctuary Advisors LLC’s holdings in Medpace were worth $1,738,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Iron Triangle Partners LP purchased a new position in shares of Medpace in the 3rd quarter valued at about $64,371,000. Wellington Management Group LLP grew its stake in Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after acquiring an additional 109,886 shares during the period. DF Dent & Co. Inc. increased its stake in Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock worth $53,841,000 after buying an additional 105,659 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Medpace during the third quarter worth $23,321,000. Finally, International Assets Investment Management LLC raised its position in shares of Medpace by 38,432.9% in the third quarter. International Assets Investment Management LLC now owns 57,414 shares of the company’s stock valued at $19,165,000 after buying an additional 57,265 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $381.44.

Medpace Price Performance

NASDAQ MEDP opened at $344.35 on Tuesday. The company has a market cap of $10.49 billion, a P/E ratio of 27.26, a P/E/G ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The stock has a 50-day moving average of $343.13 and a two-hundred day moving average of $346.83.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.